Marmon Shana, Strober Bruce E
Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, New York, USA.
Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, New York, USA.
J Invest Dermatol. 2008 Nov;128(11):2567-2569. doi: 10.1038/jid.2008.291.
Although effective in the treatment of immunodysregulatory diseases such as psoriasis, targeted immunosuppressive agents may confer risks of both enhanced susceptibility to infection and decreased responsiveness to vaccination. In a recent study, Krueger et al. (this issue) investigated these issues by testing the immune response to both a model antigen and a therapeutic vaccination in psoriasis patients during and after treatment with an LFA-1 inhibitor, efalizumab.
Zotero 插件